AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18711222 — intervention group
Group type: COMPARATOR
Intervention: GFR <45 ml/min/1.73 m² BSA
Number of subjects: 3527
Study 16428496 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPPEBVCAD chemotherapy with limited radiotherapy
Number of subjects: 307
Study 16428496 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPPEBVCAD chemotherapy
Number of subjects: 307
Study 15077576 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11917836 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured proforma for written communication with the ED
Number of subjects: 155
Study 11917836 — intervention group
Group type: COMPARATOR
Intervention: Usual referral procedures (Control)
Number of subjects: 155
Study 9894256 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Radiotherapy and endocrine therapy)
Number of subjects: 0
Study 9894256 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 0
Study 9894256 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy and radical prostatectomy
Number of subjects: 0
Study 9894256 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant endocrine therapy
Number of subjects: 0
Study 9894256 — intervention group
Group type: COMPARATOR
Intervention: Single-agent therapy (Radiotherapy and radical prostatectomy)
Number of subjects: 0
Study 9894256 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 0
Study 7843425 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (NET) during the luteal phase of the previous cycle
Number of subjects: 80
Study 7843425 — intervention group
Group type: COMPARATOR
Intervention: No norethisterone acetate (NET) during the luteal phase of the previous cycle (Control group)
Number of subjects: 80
Study 7843425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received gonadotropin-releasing hormone agonist in follicular phase (flare-up) protocols
Number of subjects: 80
Study 2196021 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 140
Study 2196021 — intervention group
Group type: COMPARATOR
Intervention: No digoxin (Control)
Number of subjects: 140
Study 26318 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of nasogastric tube
Number of subjects: 146
Study 26318 — intervention group
Group type: COMPARATOR
Intervention: Absence of nasogastric tube
Number of subjects: 146
Study 26318 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced anesthetist
Number of subjects: 146
Study 26318 — intervention group
Group type: COMPARATOR
Intervention: Experienced anesthetist
Number of subjects: 146
Study 26318 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 146
Study 7052188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin (Adriamycin) and 5‐fluorouracil
Number of subjects: 30
Study 7052188 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate, doxorubicin and 5‐fluorouracil with folinic acid rescue
Number of subjects: 30
Study 30943454 — intervention group
Group type: EXPERIMENTAL
Intervention: Taped
Number of subjects: 12
Study 30943454 — intervention group
Group type: EXPERIMENTAL
Intervention: Braced
Number of subjects: 12
Study 30943454 — intervention group
Group type: EXPERIMENTAL
Intervention: FRT
Number of subjects: 12
Study 30943454 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 29972712 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical solution of 0.25% finasteride admixed with 3% minoxidil
Number of subjects: 40
Study 29972712 — intervention group
Group type: COMPARATOR
Intervention: 3% minoxidil solution
Number of subjects: 40
Study 26585431 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral prednisolone
Number of subjects: 92
Study 26585431 — intervention group
Group type: COMPARATOR
Intervention: Medium-dose oral prednisolone
Number of subjects: 92
Study 24645912 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrated foot (soaked in water)
Number of subjects: 0
Study 24645912 — intervention group
Group type: COMPARATOR
Intervention: Non-hydrated foot (control)
Number of subjects: 0
Study 22452604 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic multistrain treatment for 10 days
Number of subjects: 40
Study 22452604 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 22452604 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic multistrain treatment
Number of subjects: 40
Study 22452604 — intervention group
Group type: EXPERIMENTAL
Intervention: Second line therapy for remaining positive patients
Number of subjects: 40
Study 20101011 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted tai chi program (4 times 30 min/wk)
Number of subjects: 160
Study 20101011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition‐action program (2 times 30-45 min/wk)
Number of subjects: 160
Study 20101011 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 160
Study 17625080 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil therapy
Number of subjects: 25
Study 17625080 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 25
Study 16040714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary vitamin C with L-NMMA and dobutamine
Number of subjects: 11
Study 16040714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary L-NMMA plus dobutamine
Number of subjects: 11
Study 16040714 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dobutamine alone
Number of subjects: 11
Study 11788633 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens (PE) supplementation 150 mg/d
Number of subjects: 36
Study 11788633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10086834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegretol (reference product)
Number of subjects: 0
Study 10086834 — intervention group
Group type: COMPARATOR
Intervention: Generic carbamazepine products
Number of subjects: 0
Study 10086834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cmax/AUCpart
Number of subjects: 0
Study 10086834 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial AUC
Number of subjects: 0
Study 7593378 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of an extended-life disposable filter
Number of subjects: 12
Study 7593378 — intervention group
Group type: COMPARATOR
Intervention: No filter
Number of subjects: 12
Study 7593378 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group comparison
Number of subjects: 12
Study 2246375 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety management training focused on coping with anger and hostility
Number of subjects: 0
Study 2246375 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant self-control procedures
Number of subjects: 0
Study 2246375 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 7364496 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous D. pteronyssinus extract
Number of subjects: 29
Study 7364496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31072967 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (10 IU) administered intravenously within 15 seconds of birth
Number of subjects: 144
Study 31072967 — intervention group
Group type: COMPARATOR
Intervention: Control group (oxytocin administered after clamping the umbilical cord 3 min after delivery)
Number of subjects: 144
Study 31072967 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 144
Study 30367542 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional change applied to patients in the experimental group (EG) with head of the bed elevated by 45-60°.
Number of subjects: 200
Study 30367542 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) in a supine position with head of the bed elevated to 15°.
Number of subjects: 200
Study 28861888 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingfei Mixture + azithromycin
Number of subjects: 46
Study 28861888 — intervention group
Group type: EXPERIMENTAL
Intervention: azithromycin + Qingfei Mixture
Number of subjects: 46
Study 28861888 — intervention group
Group type: COMPARATOR
Intervention: azithromycin
Number of subjects: 46
Study 28861888 — intervention group
Group type: COMPARATOR
Intervention: Qingfei Mixture
Number of subjects: 46
Study 25193142 — intervention group
Group type: EXPERIMENTAL
Intervention: PEERS intervention
Number of subjects: 0
Study 25193142 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 23833983 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity observation using resting state fMRI in patients with sudden deafness
Number of subjects: 12
Study 23833983 — intervention group
Group type: COMPARATOR
Intervention: Normal hearing group (control)
Number of subjects: 12
Study 22086154 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral vaporization (TUVP)
Number of subjects: 90
Study 22086154 — intervention group
Group type: COMPARATOR
Intervention: Standard transurethral resection of the prostate (TURP)
Number of subjects: 90
Study 19594549 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Prick Test (SPT) with 7 mm egg white
Number of subjects: 157
Study 19594549 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Prick Test (SPT) with 9 mm egg white
Number of subjects: 157
Study 19594549 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE (sIgE) level of 1.5 KU/L for egg white
Number of subjects: 157
Study 19594549 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE (sIgE) level of 25 KU/L for egg white
Number of subjects: 157
Study 19594549 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Prick Tests (SPTs) with ovotransferrin and lysozyme
Number of subjects: 157
Study 19594549 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Prick Tests (SPTs) with yolk and ovalbumin
Number of subjects: 157
Study 17467151 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (VX-950)
Number of subjects: 19
Study 17467151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15173716 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump beating heart surgery
Number of subjects: 37
Study 15173716 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary bypass surgery
Number of subjects: 37
Study 11561142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 40
Study 11561142 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus amikacin
Number of subjects: 40
Study 9250235 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) with spacer devices
Number of subjects: 507
Study 9250235 — intervention group
Group type: COMPARATOR
Intervention: Wet nebulizer
Number of subjects: 507
Study 7695059 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation homes
Number of subjects: 30
Study 7695059 — intervention group
Group type: COMPARATOR
Intervention: Control group (unchanged conditions)
Number of subjects: 30
Study 2888801 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (M) 1.35 g/day
Number of subjects: 46
Study 2888801 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (S) 4.5 g/day
Number of subjects: 46
Study 31928120 — intervention group
Group type: EXPERIMENTAL
Intervention: Symax hip stem
Number of subjects: 45
Study 31375874 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk powder fortified with vitamin D 400 IU plus calcium 600 mg (Ca6D)
Number of subjects: 232
Study 31375874 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk powder fortified with vitamin D 400 IU plus calcium 300 mg (Ca3D)
Number of subjects: 232
Study 31375874 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk powder fortified with vitamin D 400 IU plus calcium 900 mg (Ca9D)
Number of subjects: 232
Study 31375874 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining habitual diet
Number of subjects: 232
Study 29045514 — intervention group
Group type: EXPERIMENTAL
Intervention: ALK inhibitor (ALKi)
Number of subjects: 0
Study 29045514 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody (Ab)
Number of subjects: 0
Study 25728208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 134
Study 25728208 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole and/or Vancomycin
Number of subjects: 134
Study 23793805 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 164
Study 23793805 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 164
Study 21518978 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral catheter-based renal denervation
Number of subjects: 50
Study 21518978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 19837434 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil for 4 weeks
Number of subjects: 60
Study 19837434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16960937 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment for 28 weeks
Number of subjects: 36
Study 16960937 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no treatment)
Number of subjects: 36
Study 12806564 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic review and meta-analysis procedures
Number of subjects: 0
Study 12806564 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis procedures
Number of subjects: 0
Study 12806564 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse variance method
Number of subjects: 0
Study 12806564 — intervention group
Group type: EXPERIMENTAL
Intervention: Validity assessment of systematic reviews
Number of subjects: 0
Study 12806564 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of systematic review results
Number of subjects: 0
Study 10934782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidim (CTZ) 1 g i.v.
Number of subjects: 75
Study 10934782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPF) 400 mg i.v.
Number of subjects: 75
Study 10934782 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (CLIN) 900 mg i.v.
Number of subjects: 75
Study 9241108 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 1484
Study 9241108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine
Number of subjects: 1484
Study 1584258 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage
Number of subjects: 82
Study 3882617 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 277
Study 3882617 — intervention group
Group type: COMPARATOR
Intervention: Ionic media (meglumine iothalamate and meglumine-Na diatrizoate)
Number of subjects: 277
Study 3882617 — intervention group
Group type: EXPERIMENTAL
Intervention: All media studied (including iohexol and ionic media)
Number of subjects: 277
Study 29276844 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diet interventions
Number of subjects: 69
Study 29276844 — intervention group
Group type: COMPARATOR
Intervention: Exercise intervention (Control)
Number of subjects: 69
Study 29150857 — intervention group
Group type: EXPERIMENTAL
Intervention: 170 μg LPP
Number of subjects: 198
Study 29150857 — intervention group
Group type: EXPERIMENTAL
Intervention: 370 μg LPP
Number of subjects: 198
Study 29150857 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 μg LPP
Number of subjects: 198
Study 29150857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 29150857 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (70 μg, 170 μg, 370 μg)
Number of subjects: 198
Study 25927221 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise tapering of remifentanil from 0.3 to 0.1 μg/kg/min for at least 30 minutes (Group B)
Number of subjects: 62
Study 25927221 — intervention group
Group type: COMPARATOR
Intervention: High-dose remifentanil infused at 0.3 μg/kg/min until the end of surgery (Group A)
Number of subjects: 62
Study 23565623 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually paced breathing at 0.14 Hz
Number of subjects: 20
Study 23565623 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually paced breathing at 0.10 Hz
Number of subjects: 20
Study 23565623 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually paced breathing at 0.06 Hz
Number of subjects: 20
Study 23565623 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting frequency
Number of subjects: 20
Study 23565623 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep and slow breathing (DSB)
Number of subjects: 20
Study 23565623 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline-to-DSB and session-to-session differences in RR-interval
Number of subjects: 20
Study 23565623 — intervention group
Group type: EXPERIMENTAL
Intervention: SDRR and respiratory CO2
Number of subjects: 20
Study 21320737 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan (GNN) 2.52 g/d for 4 weeks
Number of subjects: 80
Study 21320737 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 80
Study 19590588 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 17420403 — intervention group
Group type: EXPERIMENTAL
Intervention: Retigabine 600 mg/day
Number of subjects: 399
Study 17420403 — intervention group
Group type: EXPERIMENTAL
Intervention: Retigabine 900 mg/day
Number of subjects: 399
Study 17420403 — intervention group
Group type: EXPERIMENTAL
Intervention: Retigabine 1,200 mg/day
Number of subjects: 399
Study 17420403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 15482042 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence reinforcement with take-home methadone doses for opiate- and cocaine-free urine samples
Number of subjects: 78
Study 15482042 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence reinforcement with take-home methadone doses and 5,800 US dollars in vouchers for cocaine-free urine samples
Number of subjects: 78
Study 15482042 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 78
Study 11470017 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0
Study 11470017 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0
Study 7892015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral (CB) intervention followed by usual TMD treatment
Number of subjects: 0
Study 7892015 — intervention group
Group type: COMPARATOR
Intervention: Usual TMD treatment
Number of subjects: 0
Study 7892015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral (CB) intervention
Number of subjects: 0
Study 3362846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric beer
Number of subjects: 14
Study 3362846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrajejunal beer
Number of subjects: 14
Study 3362846 — intervention group
Group type: COMPARATOR
Intervention: Glucose (5.6%, w/v) intragastrically
Number of subjects: 14
Study 3362846 — intervention group
Group type: COMPARATOR
Intervention: Glucose (5.6%, w/v) intrajejunally
Number of subjects: 14
Study 30070567 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 16
Study 30070567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27914651 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised functional restoration plus guideline-based advice
Number of subjects: 96
Study 27914651 — intervention group
Group type: COMPARATOR
Intervention: Advice alone
Number of subjects: 96
Study 25877340 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Planning
Number of subjects: 2565
Study 25877340 — intervention group
Group type: COMPARATOR
Intervention: Rapid Implementation
Number of subjects: 2565
Study 23193208 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of barriers to self-care and strategies to cope with these barriers
Number of subjects: 100
Study 23193208 — intervention group
Group type: COMPARATOR
Intervention: Attention control (usual care)
Number of subjects: 100
Study 21255059 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release mesalazine 4.8 g/day
Number of subjects: 391
Study 21255059 — intervention group
Group type: COMPARATOR
Intervention: Delayed-release mesalazine 2.4 g/day
Number of subjects: 391
Study 18287365 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin group (n = 127) took a daily supplement containing 1000 microg folate, 500 microg vitamin B‐12, and 10 mg vitamin B‐6 for 2 years
Number of subjects: 253
Study 18287365 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 253
Study 16943535 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer treatment (surgery, radiotherapy, watchful waiting, hormone therapy)
Number of subjects: 2211
Study 16943535 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 2211
Study 14584860 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF-BB (0.5 mg/ml, 1.0 mg/ml, or 5.0 mg/ml) with demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 9
Study 14584860 — intervention group
Group type: COMPARATOR
Intervention: ABB-C (anorganic bovine bone in collagen) with a bilayer collagen membrane
Number of subjects: 9
Study 14584860 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF/allograft
Number of subjects: 9
Study 14584860 — intervention group
Group type: COMPARATOR
Intervention: ABB-C and membrane
Number of subjects: 9
Study 10930195 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 26
Study 10930195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9282197 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% cocaine
Number of subjects: 60
Study 9282197 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 9282197 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% cocaine and normal saline (both sides)
Number of subjects: 60
Study 8494508 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 30
Study 8494508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30